Bron

• DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL Recruiting
  2025-522687-33-00 5 2026-05-19 Stroke
• Cerebral hemodynamic optimization by milrinone for the prevention of delayed cerebral ischemia in severe subarachnoid hemorrhage Recruiting
  2024-513410-35-00 5 2026-05-12 aneurysmal subarachnoid hemorrhage
• A PET-MRI study of serotoninergic brainstem pathway in patients with Dravet Syndrome - DRAPETONINE Recruiting
  2025-524199-40-00 4 2026-05-04 neurology
• COMMODITIES : Comparison of initial dual oral COMbination therapy to MOnotherapy in pulmonary arterial hypertension with cardiovascular como … Recruiting
  2023-509891-40-00 5 2026-04-28 Pulmonary arterial hypertension
• Efficacy of early continuous infusion of hypertonic saline solution on the neurological outcome at 6 months in traumatic brain injured patie … Recruiting
  2024-520205-39-00 5 2026-04-21 Traumatic brain injury
• A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Statur … Recruiting
  2025-523079-44-00 5 2026-04-15 Turner Syndrome (TS)
• A study to test whether nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis Recruiting
  2025-522383-33-00 5 2026-03-23 Interstitial lung diseases
• Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com … Recruiting
  2025-521284-12-00 5 2026-03-05 Non-small cell lung cancer
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• A phase 2, randomized, double-blind study of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease. Recruiting
  2025-522146-40-00 4 2026-02-12 Late-onset Pompe disease.
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part … Recruiting
  2025-522151-26-00 5 2026-02-06 Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growt
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• Randomised, controlled phase II proof-of-concept trial to assess the efficacy of abaCavIr/lamivudine treatment on the interferon signature i … Recruiting
  2023-508611-22-00 4 2026-02-03 systemic lupus
• Long-Term Extension Study of Vosoritide to Treat Children with Hypochondroplasia Recruiting
  2024-517238-16-00 5 2026-01-28 Hypochondroplasia
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• ​​Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting
  2024-519404-27-00 5 2026-01-16 ​​IDH-mutant grade 2 or 3 astrocytoma​
• An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with S … Recruiting
  2024-520208-25-00 4 2026-01-15 Still’s disease
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RET … Recruiting
  2024-516244-25-00 5 2026-01-06 Kawasaki disease
• A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab … Recruiting
  2024-519494-19-00 5 2025-12-22 Nutritional and metabolic diseases
• INFLANET - A French Network for PET imaging of neuroinflammation in MS Recruiting
  2023-510304-53-00 10 2025-12-16 Multiple sclerosis
• EPIK-P4: A Phase II single-arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patien … Recruiting
  2024-519960-42-00 4 2025-12-11 PIK3CA-Related Overgrowth Spectrum (PROS)
• PHASE 2B TRIAL OF AEF0217 IN PARTICIPANTS WITH DOWN SYNDROME Recruiting
  2025-521013-10-00 4 2025-12-11 Treatment of behavioural and cognitive impairments in Down syndrome.

Showing 97–120 of 434 trials